As indicated by the marked Gradient 1-alignment of AD pathology (driven by tau) in the cognitively unimpaired group, using gradient alignment as a biomarker might enable identification of early cognitive vulnerability before clinical symptoms emerge. The gene discussed is MAPT; the disease is Alzheimer disease.